```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 10  Time limit for inactive STN sessions doubles to 40
                  minutes
 NEWS  3  AUG 18  COMPENDEX indexing changed for the Corporate Source
                  (CS) field
 NEWS  4  AUG 24  ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
 NEWS  5  AUG 24  CA/CAplus enhanced with legal status information for
                  U.S. patents
 NEWS  6  SEP 09  50 Millionth Unique Chemical Substance Recorded in
                  CAS REGISTRY
 NEWS  7  SEP 11  WPIDS, WPINDEX, and WPIX now include Japanese FTERM
                  thesaurus
 NEWS  8  OCT 21  Derwent World Patents Index Coverage of Indian and
                  Taiwanese Content Expanded
 NEWS  9  OCT 21  Derwent World Patents Index enhanced with human
                  translated claims for Chinese Applications and
                  Utility Models
 NEWS 10  OCT 27  Free display of legal status information in CA/CAplus,
                  USPATFULL, and USPAT2 in the month of November.
 NEWS 11  NOV 23  Addition of SCAN format to selected STN databases
 NEWS 12  NOV 23  Annual Reload of IFI Databases

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:08:16 ON 23 NOV 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY     SESSION
FULL ESTIMATED COST                                     0.22        0.22
```

FILE 'REGISTRY' ENTERED AT 19:08:27 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10535268.str

chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
15
chain bonds :
4-7 7-8 7-9 9-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-8 7-9 9-10 11-12
exact bonds :
10-11
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 19:08:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11603 TO ITERATE

17.2% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 225604 TO 238516
PROJECTED ANSWERS: 1 TO 260

L2 1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 19:08:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 230123 TO ITERATE

100.0% PROCESSED 230123 ITERATIONS 256 ANSWERS
SEARCH TIME: 00.00.05

L3 256 SEA SSS FUL L1

=> d scan

L3 256 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-(2-imino[1,4'-bipiperidin]-1'-yl)-, (2S)-
MF C23 H28 Cl N3 O4 S
CI COM

Absolute stereochemistry.



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   185.88     186.10

FILE 'CAPLUS' ENTERED AT 19:09:15 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Nov 2009  VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009  (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.

=> d his

     (FILE 'HOME' ENTERED AT 19:08:16 ON 23 NOV 2009)

     FILE 'REGISTRY' ENTERED AT 19:08:27 ON 23 NOV 2009
L1             STRUCTURE UPLOADED
L2               1 S L1
L3             256 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 19:09:15 ON 23 NOV 2009

=> s l3 and (pry<2003 or py<2003)
             20 L3
        3991119 PRY<2003
       22992685 PY<2003
```

```
L4          12 L3 AND (PRY<2003 OR PY<2003)

=> s 1-12 ibib abs hitstr
      10416407 1
       1682331 12
            16 IBIB
        256174 ABS
             3 ABSES
        256177 ABS
                (ABS OR ABSES)
L5           0 1-12 IBIB ABS HITSTR
               (1(W)12(W)IBIB(W)ABS(W)HITSTR)

=> s l4
            20 L3
       3991119 PRY<2003
      22992685 PY<2003
L6          12 L3 AND (PRY<2003 OR PY<2003)

=> d 1-12 ibib abs hitstr

L6   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:1300802  CAPLUS
DOCUMENT NUMBER:          149:513860
TITLE:                    Preparation of pyrazolopyrimidines as cyclin-dependent
                          kinase inhibitors
INVENTOR(S):              Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
                          Doll, Ronald; Girijavallabhan, Viyyoor M.; Mallams,
                          Alan; Alvarez, Carmen S.; Keertikar, Kartik M.;
                          Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.;
                          Fischmann, Thierry O.; Kirschmeier, Paul; Bannerji,
                          Rajat; Dillard, Lawrence W.; Tran, Vinh D.; He,
                          Zhenmin; James, Ray Anthony; Park, Haengsoon;
                          Paradkar, Vidyadhar M.; Hobbs, Douglas W.
PATENT ASSIGNEE(S):       Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE:                   PCT Int. Appl., 635pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   8
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2008130570        A1    20081030    WO 2008-US4907         20080416
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     US 20080050384       A1    20080228    US 2007-788847         20070420 <--
PRIORITY APPLN. INFO.:                     US 2007-788847      A  20070420
                                           US 2002-408027P     P  20020904 <--
                                           US 2002-421959P     P  20021029 <--
                                           US 2003-654546      A2 20030903
```

US 2004-776988 A3 20040211
US 2006-396079 B2 20060331
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:513860
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

IT 677789-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1300618 CAPLUS
DOCUMENT NUMBER: 149:513859
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 723pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130569	A1	20081030	WO 2008-US4906	20080416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070281951	A1	20071206	US 2007-788856	20070420 <--
PRIORITY APPLN. INFO.:			US 2007-788856	A 20070420
			US 2002-408027P	P 20020904 <--
			US 2002-421959P	P 20021029 <--
			US 2003-654546	A2 20030903
			US 2004-776988	A2 20040211
			US 2005-245401	A3 20051006
			US 2007-710644	A2 20070223

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:513859
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

IT 677789-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:251311 CAPLUS
DOCUMENT NUMBER: 148:308364
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhenmin; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh; Kirschmeier, Paul; Bannerji, Rajat
PATENT ASSIGNEE(S): Shering Corporation and Pharmacopeia, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 387 pp., Cont.-in-part of U.S. Ser. No. 396,079.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080050384	A1	20080228	US 2007-788847	20070420 <--
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
US 20070054925	A1	20070308	US 2006-396079	20060331 <--
WO 2008130570	A1	20081030	WO 2008-US4907	20080416

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2002-408027P	P	20020904 <--
US 2002-421959P	P	20021029 <--
US 2003-654546	A2	20030903
US 2004-776988	A3	20040211
US 2006-396079	B2	20060331
CN 2003-824997	A3	20030903
US 2007-788847	A	20070420

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:308364

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

IT 677789-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1395785 CAPLUS
DOCUMENT NUMBER: 148:55084
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S. Ser. No. 710,644.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070281951	A1	20071206	US 2007-788856	20070420 <--
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
US 20060128725	A1	20060615	US 2005-245401	20051006 <--
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
US 20070225270	A1	20070927	US 2007-710644	20070223 <--
WO 2008130569	A1	20081030	WO 2008-US4906	20080416

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2002-408027P	P	20020904 <--
US 2002-421959P	P	20021029 <--
US 2003-654546	A2	20030903
US 2004-776988	A2	20040211
US 2005-245401	A3	20051006
US 2007-710644	A2	20070223
CN 2003-824997	A3	20030903
US 2007-788856	A	20070420

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:55084

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

IT 677789-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:579598 CAPLUS
DOCUMENT NUMBER: 145:62916
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S. Ser. No. 776,988.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128725	A1	20060615	US 2005-245401	20051006 <--
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903 <--
US 7161003	B2	20070109	US 2003-654546	20030903 <--
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211 <--
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117 <--
US 20070072881	A1	20070329	US 2006-542920	20061004 <--
US 7605155	B2	20091020		
AU 2006302443	A1	20070419	AU 2006-302443	20061004
CA 2624829	A1	20070419	CA 2006-2624829	20061004
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1931677	A2	20080618	EP 2006-836186		20061004	
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS						
JP 2009511487	T	20090319	JP 2008-534679		20061004	
BR 200616987	A2	20090804	BR 2006-16987		20061004	
US 20070225270	A1	20070927	US 2007-710644		20070223	<--
US 20070281951	A1	20071206	US 2007-788856		20070420	<--
IN 2008CN01697	A	20081226	IN 2008-CN1697		20080404	
ZA 2008002996	A	20090325	ZA 2008-2996		20080404	
MX 2008004665	A	20080617	MX 2008-4665		20080407	
KR 2008063796	A	20080707	KR 2008-710183		20080428	
NO 2008002091	A	20080704	NO 2008-2091		20080505	
CN 101321756	A	20081210	CN 2006-80045338		20080602	
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904	<--
			US 2002-421959P	P	20021029	<--
			US 2003-654546	A2	20030903	
			US 2004-776988	A2	20040211	
			CN 2003-824997	A3	20030903	
			US 2005-245401	A2	20051006	
			WO 2006-US38939	W	20061004	
			US 2007-710644	A2	20070223	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 145:62916
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.

IT 677789-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:980998 CAPLUS

DOCUMENT NUMBER: 141:379942

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.

SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904	<--
			US 2002-421959P	P	20021029	<--
			US 2003-654546	A2	20030903	
			US 2004-776988	A	20040211	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

GI



I



II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677789-58-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:467881 CAPLUS
DOCUMENT NUMBER: 141:38631
TITLE: Imidazole derivative, process for producing the same, and use
INVENTOR(S): Kubo, Keiji; Kuroita, Takanobu; Imaeda, Yasuhiro; Kawamura, Masaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 318 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048363	A1	20040610	WO 2003-JP14793	20031120 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507026	A1	20040610	CA 2003-2507026	20031120 <--
AU 2003284596	A1	20040618	AU 2003-284596	20031120 <--
EP 1564213	A1	20050817	EP 2003-774086	20031120 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004182730	A	20040702	JP 2003-392992	20031121 <--
US 20070004736	A1	20070104	US 2006-535268	20060519 <--
PRIORITY APPLN. INFO.:			JP 2002-338939 A	20021122 <--
			WO 2003-JP14793 W	20031120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:38631
GI

I

AB Imidazole derivs. represented by the formula (I) [wherein R = each optionally substituted cyclic hydrocarbon group or heterocyclic group; W = a bond, optionally substituted divalent chain hydrocarbon group; X = optionally substituted divalent hydrocarbon group; Y = CO, S(O), S(O)2, a bond; ring A = each optionally substituted pyrrolidine ring, piperidine ring, or perhydroazepine ring; Z1, Z3 = each independently a bond or optionally substituted divalent chain hydrocarbon group; Z2 = N(R1), O, S(O), S(O)2, CO, CH(R1), a bond; ring B = an optionally substituted imidazole ring, provided that a substituent of the imidazole ring represented by B may be bonded to R1 to form an optionally substituted ring; m = 0, 1, 2] are prepared These imidazole derivs. are inhibitors of activated blood coagulation factor X (FXa) and useful as anticoagulants for the prevention and/or treatment of myocardial infarction, cerebral infarction, deep venous thrombosis, pulmonary thromboembolism and embolism, obstructive arteriosclerosis, economy class syndromes, thromboembolism and embolism during or after surgery, or the second onset of deep venous thrombosis. Thus, 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one was condensed with 3-[(6-chloro-2-naphthyl)sulfonyl]propionic acid using HOBt, Et3N, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 to give 52% 2-[1-[3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl]-4-piperidinyl]-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one (II). II showed IC50 of 5.6 nM for inhibiting FXa. Pharmaceutical formulations, e.g. a gelatine capsule containing II, were described.

IT

701295-58-1P	701295-60-5P	701295-62-7P
701295-63-8P	701295-65-0P	701295-67-2P
701295-69-4P	701295-70-7P	701295-71-8P
701295-72-9P	701295-73-0P	701295-74-1P
701295-75-2P	701295-76-3P	701295-77-4P
701295-78-5P	701296-00-6P	701296-01-7P
701296-02-8P	701296-03-9P	701296-04-0P
701296-05-1P	701296-06-2P	701296-07-3P
701296-12-0P	701296-13-1P	701296-14-2P
701296-15-3P	701296-16-4P	701296-17-5P
701296-18-6P	701296-19-7P	701296-20-0P
701296-21-1P	701296-22-2P	701296-23-3P
701296-24-4P	701296-25-5P	701296-26-6P
701296-27-7P	701296-28-8P	701296-29-9P
701296-30-2P	701296-31-3P	701296-32-4P
701296-33-5P	701296-42-6P	701296-44-8P
701296-46-0P	701296-99-3P	701297-00-9P
701297-01-0P	701297-02-1P	701297-03-2P
701297-04-3P	701297-05-4P	701297-07-6P
701297-08-7P	701297-09-8P	701297-10-1P
701297-11-2P	701297-12-3P	701297-13-4P
701297-15-6P	701297-16-7P	701297-17-8P
701297-18-9P	701297-19-0P	701297-21-4P
701297-23-6P	701297-25-8P	701297-26-9P
701297-27-0P	701297-28-1P	701297-29-2P
701297-30-5P	701297-31-6P	701297-32-7P
701297-33-8P	701297-34-9P	701297-35-0P
701297-36-1P	701297-37-2P	701297-38-3P
701297-40-7P	701297-41-8P	701297-42-9P
701297-43-0P	701297-44-1P	701297-45-2P
701297-46-3P	701297-47-4P	701297-48-5P

701297-49-6P 701297-50-9P 701297-51-0P
701297-52-1P 701297-53-2P 701297-54-3P
701297-55-4P 701297-56-5P 701297-57-6P
701297-58-7P 701297-59-8P 701297-60-1P
701297-61-2P 701297-62-3P 701297-63-4P
701297-64-5P 701297-65-6P 701297-66-7P
701297-67-8P 701297-68-9P 701297-71-4P
701297-72-5P 701297-73-6P 701297-74-7P
701297-75-8P 701297-76-9P 701297-77-0P
701297-78-1P 701297-79-2P 701297-80-5P
701297-89-4P 701298-05-7P 701298-08-0P
701298-10-4P 701298-11-5P 701911-96-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as inhibitors of activated blood coagulation factor X and antithrombotics)

RN 701295-58-1 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-60-5 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-62-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-63-8 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-65-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(4-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-67-2 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(4-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-69-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2,4-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-70-7 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(2,4-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-71-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-ethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-72-9 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(1-methylethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-73-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-propyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-74-1 CAPLUS
CN 1-Propanone, 1-[4-(2-butyl-1H-imidazol-1-yl)-1-piperidinyl]-3-[(6-chloro-2-naphthalenyl)sulfonyl]- (CA INDEX NAME)



RN 701295-75-2 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(hydroxymethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-76-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(2-hydroxyethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-77-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(4,5-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-78-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-00-6 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-3-methyl- (CA INDEX NAME)



RN 701296-01-7 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-methyl- (CA INDEX NAME)



RN 701296-02-8 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-ethyl- (CA INDEX NAME)



RN 701296-03-9 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-ethyl-3-methyl- (CA INDEX NAME)



RN 701296-04-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-ethyl-1,2-dihydro- (CA INDEX NAME)



RN 701296-05-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-methyl-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701296-06-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(4-bromophenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701296-07-3 CAPLUS
CN 5H-Imidazo[1,5-a]imidazol-5-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro-2-methyl-

(CA INDEX NAME)



RN 701296-12-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 701296-13-1 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(1H-imidazol-5-ylmethyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-14-2 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(2-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-15-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-16-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(1H-imidazol-2-ylmethyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-17-5 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(1H-imidazol-5-ylmethyl)- (CA INDEX NAME)



RN 701296-18-6 CAPLUS
CN Methanesulfonamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(1H-imidazol-5-ylmethyl)- (CA INDEX NAME)



RN 701296-19-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[ethyl[(2-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-20-0 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-[(2-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)



RN 701296-21-1 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-3-methyl- (CA INDEX NAME)



RN 701296-22-2 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-[(4-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)



RN 701296-23-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[ethyl[(4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-24-4 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro- (CA INDEX NAME)



RN 701296-25-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(5,6-dihydro-3-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-26-6 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-1,5-dimethyl- (CA INDEX NAME)



RN 701296-27-7 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 7-chloro-2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)



RN 701296-28-8 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-1-methyl- (CA INDEX NAME)



RN 701296-29-9 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(5,6-dihydro-1-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-30-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701296-31-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701296-32-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-1,7-dimethyl- (CA INDEX NAME)



RN 701296-33-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5,7-dimethyl- (CA INDEX NAME)



RN 701296-42-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-ethyl-1,2-dihydro-7-methyl- (CA INDEX NAME)



RN 701296-44-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)



RN 701296-46-0 CAPLUS
CN 2-Propenamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(4-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 701296-99-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-00-9 CAPLUS
CN 1H-Imidazo[1,5-c]imidazole-1,3(2H)-dione, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 701297-01-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-02-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 701297-03-2 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro-5-hydroxy-3-methyl- (CA INDEX NAME)



RN 701297-04-3 CAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro- (CA INDEX NAME)



RN 701297-05-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(5-chloro-1H-indol-2-yl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-07-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-08-7 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[2-[(6-chloro-2-naphthalenyl)sulfonyl]-3-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-09-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-10-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(hydroxymethyl)- (CA INDEX NAME)



RN 701297-11-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 5-[(acetyloxy)methyl]-2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701297-12-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-13-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 5-[(benzoyloxy)methyl]-2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 701297-15-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-2-methyl-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701297-16-7 CAPLUS
CN Carbamic acid, [1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701297-17-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[2-amino-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701297-18-9 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-19-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 701297-21-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[(6-chloro-2-naphthalenyl)sulfonyl]-3-methyl-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-23-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[[2-(4-chlorophenyl)ethyl]sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-25-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-26-9 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-27-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-2-amino-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 701297-28-1 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-

methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-29-2 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-30-5 CAPLUS
CN Methanesulfonamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-31-6 CAPLUS
CN Benzenesulfonamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-

oxoethyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-32-7 CAPLUS
CN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-N'-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-33-8 CAPLUS
CN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-34-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-35-0 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-36-1 CAPLUS
CN Carbamic acid, [(1R)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-37-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxo-2-(phenylamino)propyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-38-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-40-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-41-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-42-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 2-(phenylmethoxy)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-43-0 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-

oxoethyl]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-44-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxo-2-(2-oxo-3-oxazolidinyl)propyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-45-2 CAPLUS
CN Carbamic acid, [(2S)-2-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-46-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-3-(methylamino)-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 701297-47-4 CAPLUS
CN Carbamic acid, cyclohexyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-48-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-49-6 CAPLUS
CN 1-Pyrrolidinepropanoic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-50-9 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-

naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-51-0 CAPLUS
CN Carbamic acid, [2-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 701297-52-1 CAPLUS
CN 1-Piperidinepropanoic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-53-2 CAPLUS
CN 1-Piperidineacetic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-54-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-55-4 CAPLUS
CN Carbamic acid, ethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-56-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-[(dimethylamino)methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-57-6 CAPLUS
CN Carbamic acid, dimethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-58-7 CAPLUS
CN β-Alanine, N-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-59-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-(fluoromethyl)-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-60-1 CAPLUS
CN L-Valine, N-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-61-2 CAPLUS
CN Carbonic acid, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-62-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-(hydroxymethyl)-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-63-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-(difluoromethyl)-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-64-5 CAPLUS
CN Acetamide, N-[[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-65-6 CAPLUS
CN Methanesulfonamide, N-[[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-66-7 CAPLUS
CN Butanoic acid, 4-(acetylamino)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-67-8 CAPLUS
CN Pentanoic acid, 5-(benzoylamino)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-68-9 CAPLUS
CN β-Alanine, N-(1-oxobutyl)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-71-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-72-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(methoxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-73-6 CAPLUS
CN β-Alanine, N-(1-oxohexyl)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 701297-74-7 CAPLUS
CN β-Alanine, N-ethyl-N-(1-oxopropyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-75-8 CAPLUS
CN β-Alanine, N-ethyl-N-(1-oxobutyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-76-9 CAPLUS
CN β-Alanine, N-acetyl-N-methyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-77-0 CAPLUS
CN β-Alanine, N-acetyl-N-ethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-

piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-78-1 CAPLUS
CN β-Alanine, N-methyl-N-(1-oxobutyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-
piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-79-2 CAPLUS
CN β-Alanine, N-methyl-N-(1-oxohexyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-80-5 CAPLUS
CN β-Alanine, N-acetyl-N-propyl-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 701297-89-4 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 701298-05-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-08-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-10-4 CAPLUS
CN 1-Propanone, 3-[(5-chloro-1H-indol-2-yl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-,

hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-11-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-methyl-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701911-96-8 CAPLUS
CN 5H-Imidazo[1,5-a]imidazol-5-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro- (CA INDEX NAME)



IT 701298-60-4P 701298-62-6P 701298-63-7P
701298-64-8P 701298-82-0P 701299-44-7P
701299-62-9P 701299-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazole derivs. as inhibitors of activated blood coagulation factor X and antithrombotics)
RN 701298-60-4 CAPLUS
CN 1-Propanone, 1-(4-amino-1-piperidinyl)-3-[(6-chloro-2-naphthalenyl)sulfonyl]- (CA INDEX NAME)



RN 701298-62-6 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-63-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[2-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-64-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[4-methyl-1-(triphenylmethyl)-1H-imidazol-5-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-82-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701299-44-7 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-chloro-2-[[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 701299-62-9 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 701299-64-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.





OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:265847 CAPLUS
DOCUMENT NUMBER: 140:321370
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-XA27555	20030903 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,

NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 1735614	A	20060215	CN 2003-824997		20030903 <--
CN 100376580	C	20080326			
CN 1880317	A	20061220	CN 2006-10101322		20030903 <--
ZA 2005001855	A	20060329	ZA 2005-1855		20060117 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904 <--
			US 2002-421959P	P	20021029 <--
			CN 2003-824997	A3	20030903

GI



I

II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677789-58-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:10480 CAPLUS
DOCUMENT NUMBER: 136:85818
TITLE: Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents
INVENTOR(S): Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Munchhof, Michael John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000661	A1	20020103	WO 2001-IB975	20010605 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412560	A1	20020103	CA 2001-2412560	20010605 <--
CA 2412560	C	20081230		
EP 1294724	A1	20030326	EP 2001-934243	20010605 <--
EP 1294724	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003001114	A2	20030828	HU 2003-1114	20010605 <--
HU 2003001114	A3	20041129		
BR 2001011561	A	20030909	BR 2001-11561	20010605 <--
JP 2004501922	T	20040122	JP 2002-505785	20010605 <--
JP 4068958	B2	20080326		
EE 200200711	A	20040615	EE 2002-711	20010605 <--
NZ 522364	A	20040924	NZ 2001-522364	20010605 <--
AU 784297	B2	20060302	AU 2001-60538	20010605 <--

AT 323704	T	20060515	AT 2001-934243	20010605	<--
ES 2257410	T3	20060801	ES 2001-934243	20010605	<--
EP 1686130	A1	20060802	EP 2006-7969	20010605	<--
EP 1686130	B1	20090218			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 100351253	C	20071128	CN 2001-811792	20010605	<--
AP 1911	A	20081031	AP 2002-2695	20010605	<--
AT 423120	T	20090315	AT 2006-7969	20010605	<--
ES 2318605	T3	20090501	ES 2006-7969	20010605	<--
IL 152771	A	20090615	IL 2001-152771	20010605	<--
TW 243820	B	20051121	TW 2001-90115016	20010620	<--
US 20020068746	A1	20020606	US 2001-891028	20010625	<--
US 6696567	B2	20040224			
IN 2002DN01075	A	20050128	IN 2002-DN1075	20021030	<--
BG 107236	A	20030930	BG 2002-107236	20021031	<--
NO 2002006030	A	20021216	NO 2002-6030	20021216	<--
NO 324934	B1	20080107			
MX 2003000068	A	20030925	MX 2003-68	20021219	<--
ZA 2002010275	A	20031219	ZA 2002-10275	20021219	<--
US 20030220353	A1	20031127	US 2003-463724	20030616	<--
US 6962993	B2	20051108			
HK 1054930	A1	20080606	HK 2003-107143	20031003	<--
US 20050197349	A1	20050908	US 2005-112307	20050421	<--
US 7192963	B2	20070320			
US 20070161666	A1	20070712	US 2007-710164	20070222	<--
PRIORITY APPLN. INFO.:			US 2000-214287P	P 20000626	<--
			EP 2001-934243	A3 20010605	<--
			WO 2001-IB975	W 20010605	<--
			US 2001-891028	A1 20010625	<--
			US 2003-463724	A1 20030616	
			US 2005-112307	A3 20050421	

OTHER SOURCE(S): MARPAT 136:85818

GI



I



II

AB The title compds. [I; R1 = NR4(CH2)yR5 (wherein y = 0-2; R4 = H, alkyl, alkylsulfonyl, etc.; R5 = substituted heterocycloalkyl); R2, R3 = H, NH2, halo, etc.], useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (no data given), were prepared, e.g., a multi-step synthesis of II was given.

IT 384337-72-8P 384337-79-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)

RN 384337-72-8 CAPLUS

CN Ethanone, 1-[4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 384337-79-5 CAPLUS
CN Ethanone, 1-[4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-(3-thiazolidinylsulfonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:762989 CAPLUS
DOCUMENT NUMBER: 135:318419
TITLE: Synthesis of substituted bipiperidines and their use as H1 antagonists
INVENTOR(S): Lawrence, Louise; Rigby, Aaron; Sanganee, Hitesh; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077101	A1	20011018	WO 2001-SE751	20010405 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA	2403012	A1	20011018	CA 2001-2403012	20010405	<--
EP	1274701	A1	20030115	EP 2001-920053	20010405	<--
EP	1274701	B1	20050629			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR	2001009922	A	20030218	BR 2001-9922	20010405	<--
CN	1433411	A	20030730	CN 2001-810683	20010405	<--
CN	1244576	C	20060308			
JP	2003530393	T	20031014	JP 2001-575574	20010405	<--
NZ	521543	A	20041029	NZ 2001-521543	20010405	<--
EP	1493743	A1	20050105	EP 2004-20599	20010405	<--
EP	1493743	B1	20080903			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, CY, TR

AT	298748	T	20050715	AT 2001-920053	20010405	<--
CN	1660839	A	20050831	CN 2004-10102245	20010405	<--
AU	2001246997	B2	20070329	AU 2001-246997	20010405	<--
AT	407131	T	20080915	AT 2004-20599	20010405	<--
ES	2311772	T3	20090216	ES 2004-20599	20010405	<--
US	20020077337	A1	20020620	US 2001-827488	20010406	<--
US	6525070	B2	20030225			
ZA	2002007700	A	20040102	ZA 2002-7700	20020925	<--
NO	2002004774	A	20021129	NO 2002-4774	20021003	<--
MX	2002009885	A	20030327	MX 2002-9885	20021007	<--
US	20040006080	A1	20040108	US 2003-341027	20030113	<--
US	6903115	B2	20050607			
US	20040014783	A1	20040122	US 2003-436582	20030513	<--
US	7238811	B2	20070703			
HK	1051193	A1	20051028	HK 2003-103424	20030514	<--
US	20050171092	A1	20050804	US 2005-76773	20050310	<--
US	7179922	B2	20070220			
US	20070179297	A1	20070802	US 2007-732411	20070403	<--

PRIORITY APPLN. INFO.:	GB 2000-8626	A	20000408 <--
	GB 2000-19111	A	20000803 <--
	SE 2000-3664	A	20001011 <--
	CN 2001-810683	A3	20010405 <--
	EP 2001-920053	A3	20010405 <--
	WO 2001-SE751	W	20010405 <--
	US 2001-827488	A3	20010406 <--
	US 2003-341027	A1	20030113
	US 2003-436582	A3	20030513

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:318419
GI



I



II

AB Title compds. I [q, s, t = 0 - 1; n, r = 0 - 5; m, p = 0 - 2; X = CH, C(O), O, S, S(O), S(O), N-; provided that when m and p are both 1 then X is not CH; Y = NHR2, OH; T = C(O), C(S), S(O), CH2; R1 = H, alkyl, aryl, heterocyclyl; R2, R47 = H, alkyl, aryl-alkyl, CO-alkyl; R3 = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, thioaryl, thioheterocyclyl] were prepared Examples include: data for over 600 compds., 4 solid oral dosage and 1 parenteral (general) formulations, a bioassay for Ca2+ flux, human eosinophil chemotaxis and H1 antagonism. E.g., 4-(3,4-dichlorophenoxy)piperidine was alkylated with 1-(tert-butoxycarbonyl)-4-piperidone (1,2-dichloroethane, NaBH(OAc)3, HOAc, 18 h, room temperature) to give an intermediate [1,4']bipiperidine. This intermediate was deprotected (DCM, TFA, 4 h, room temperature) and the resulting bipiperidine condensed with 3-methanesulfonylbenzoic acid (THF, PYBROP, (i-Pr)2NEt, 18 h, room temperature) to give example compound II isolated as the acetate salt. I are used in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

IT 367498-05-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of substituted bipiperidines and use as H1 antagonists)

RN 367498-05-3 CAPLUS

CN 1-Propanone, 1-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]-2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (54 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:453019 CAPLUS
DOCUMENT NUMBER: 135:46106
TITLE: 4-Aminopiperidine derivatives, processes for their preparation, pharmaceutical compositions, and their use as medicines, specifically as somatostatin receptor ligands
INVENTOR(S): Thurieau, Christophe; Gonzalez, Jerome; Moinet, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044191	A1	20010621	WO 2000-FR3497	20001213 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2802206	A1	20010615	FR 1999-15724	19991214 <--
FR 2802206	B1	20050422		
CA 2394086	A1	20010621	CA 2000-2394086	20001213 <--
EP 1286966	A1	20030305	EP 2000-993405	20001213 <--
EP 1286966	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002004515	A2	20030428	HU 2002-4515	20001213 <--
HU 2002004515	A3	20050428		
JP 2003516965	T	20030520	JP 2001-544681	20001213 <--
NZ 520071	A	20030630	NZ 2000-520071	20001213 <--
AU 779341	B2	20050120	AU 2001-28560	20001213 <--
CN 1207283	C	20050622	CN 2000-817177	20001213 <--
RU 2266282	C2	20051220	RU 2002-118705	20001213 <--
AT 401308	T	20080815	AT 2000-993405	20001213 <--
ES 2310529	T3	20090116	ES 2000-993405	20001213 <--
US 20040006089	A1	20040108	US 2002-130924	20020523 <--
US 7115634	B2	20061003		
HK 1054029	A1	20090529	HK 2003-106281	20030903 <--
US 20050239796	A1	20051027	US 2005-122293	20050504 <--
US 7393861	B2	20080701		
KR 2007014235	A	20070131	KR 2007-701118	20070116 <--
US 20090149652	A1	20090611	US 2008-151115	20080502 <--
PRIORITY APPLN. INFO.:			FR 1999-15724 A	19991214 <--
			WO 2000-FR3497 W	20001213 <--
			US 2002-130924 A3	20020523 <--

KR 2002-707506 A3 20020612 <--
US 2005-122293 A3 20050504
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:46106
GI



AB The invention concerns novel 4-aminopiperidine derivs. I [R1 = alkyl, alkenyl, alkynyl, (CH2)mYZ1, (CH2)mZ2, 1-benzylpiperidin-4-yl, 2-naphthylcarbamoyl, 4-benzylpiperazin-1-yl, 2-acetamidoethyl; Z1 = alkyl or (un)substituted aryl; Z2 = cyano, cyclohexenyl, bis-Ph, cycloalkyl, (un)substituted heterocycloalkyl, aryl, heteroaryl, etc.; R2 = C(Y)NHX1, C(O)X2, SO2X3; R3 = H, (un)substituted alkyl, alkenyl, alkynyl, aralkyl, C(Y)NHX1, (CH2)nC(O)X2, SO2X3, etc.; X1 = alkyl, alkenyl, alkynyl, aryl, aralkyl, etc.; X2 = wide variety of groups; X3 = alkyl, alkenyl, phenylalkenyl, CF3, (un)substituted (hetero)aryl or -aralkyl; Y = O, S; n = 0-4; m = 1-6]. Also disclosed are methods for their preparation by parallel synthesis processes in liquid and solid phase. I have good affinity for certain sub-types of somatostatin receptors, and are particularly useful for treating pathol. conditions or diseases wherein one more somatostatin receptor sub-types are involved. Claims specifically mention acromegaly, pituitary adenoma, or endocrine gastroenteropanceatic tumors in carcinoid syndrome. A table of 778 compds. I is given, and several syntheses are described in detail. For instance, N-BOC-4-piperidone underwent reductive amination with 3,3-diphenylpropylamine and NaBH(OAc)3, followed by reaction with 3-trifluoromethylphenyl isocyanate, removal of the BOC group with CF3CO2H, and reaction with Ph isocyanate, to give title compound II. Some compds. I had sub-micromolar Ki for at least one of five tested somatostatin receptor subtypes (no data).

IT 344783-02-4P 344783-21-7P 344783-40-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopiperidine derivs. as somatostatin receptor ligands)

RN 344783-02-4 CAPLUS

CN Glycine, N-[[[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl][1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 344783-21-7 CAPLUS
CN Urea, N'-butyl-N-[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 344783-40-0 CAPLUS
CN Thiourea, N'-[2-(4-morpholinyl)ethyl]-N-[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:466913 CAPLUS

DOCUMENT NUMBER: 125:142726
ORIGINAL REFERENCE NO.: 125:26717a,26720a
TITLE: Muscarine antagonists
INVENTOR(S): Thompson, Wayne J.; Sugrue, Michael F.; Ransom, Richard W.; Mallorga, Pierre J.; Bell, Ian M.; Smith, Anthony M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613262	A1	19960509	WO 1995-US13710	19951024 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5574044	A	19961112	US 1994-329757	19941027 <--
US 5691323	A	19971125	US 1995-440153	19950512 <--
CA 2200468	A1	19960509	CA 1995-2200468	19951024 <--
AU 9539674	A	19960523	AU 1995-39674	19951024 <--
AU 701127	B2	19990121		
EP 786997	A1	19970806	EP 1995-937615	19951024 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 2002515008	T	20020521	JP 1996-514691	19951024 <--

PRIORITY APPLN. INFO.: US 1994-329757 A2 19941027 <--
US 1995-440153 A2 19950512 <--
WO 1995-US13710 W 19951024 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 125:142726; MARPAT 125:142726

AB Compds., 1,3-dihydro-1-{1-[piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazol-2-ones and derivs. thereof, their preparation, method of use and pharmaceutical compns. are described. These compds. are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).

IT 179323-34-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 179323-34-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1'-[2-(4-pyridinylsulfonyl)acetyl][1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 43 THERE ARE 43 CAPLUS RECORDS THAT CITE THIS RECORD (54 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    93.34     279.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.84      -9.84

FILE 'STNGUIDE' ENTERED AT 19:16:01 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 20, 2009 (20091120/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                     1.26     280.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.84

STN INTERNATIONAL LOGOFF AT 19:26:43 ON 23 NOV 2009
```